NASDAQ:RUBY

Rubius Therapeutics Insider Trades

$24.07
+0.02 (+0.08 %)
(As of 04/16/2021 10:44 AM ET)
Add
Compare
Today's Range
$23.22
Now: $24.07▼
$24.07
50-Day Range
$8.02
MA: $20.32▼
$32.01
52-Week Range
$4.20
Now: $24.07▼
$38.71
Volume4,638 shs
Average Volume1.71 million shs
Market Capitalization$1.96 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.37

Insider Trades

Rubius Therapeutics (NASDAQ:RUBY) Insider Buying and Selling Activity

Insider Ownership Percentage: 58.40%
Insider Buying (Last 12 Months): $6,194,880.00
Insider Selling (Last 12 Months): $1,943,292.20

Insider Buying and Selling by Quarter


Rubius Therapeutics (NASDAQ RUBY) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/19/2021Ventures Fund Iv Gene FlagshipMajor ShareholderBuy210,000$29.00$6,090,000.00  
3/15/2021Maiken Keson-BrookesInsiderSell25,000$20.24$506,000.0025,000  
2/10/2021David R EpsteinDirectorSell7,404$14.79$109,505.164,726,220  
2/8/2021David R EpsteinDirectorSell89,233$14.88$1,327,787.044,726,220  
4/22/2020Christina M CoughlinInsiderBuy19,000$5.52$104,880.0019,000  
4/14/2020Pablo J CagnoniCEOBuy21,000$4.70$98,700.0021,000  
3/17/2020David R EpsteinDirectorBuy5,000$3.76$18,800.004,815,453  
3/13/2020David R EpsteinDirectorBuy10,000$3.91$39,100.004,805,453  
12/16/2019Christopher L CarpenterInsiderSell48,000$13.48$647,040.0082,843  
10/14/2019Robert LangerDirectorSell7,500$9.25$69,375.00
9/17/2019Christopher L CarpenterInsiderSell48,000$10.11$485,280.00
7/15/2019Robert LangerDirectorSell7,500$14.94$112,050.00  
6/19/2019Christopher L CarpenterInsiderSell47,757$14.02$669,553.14  
4/15/2019Robert LangerDirectorSell7,500$17.57$131,775.00  
4/8/2019Torben Straight NissenPresidentSell2,100$20.00$42,000.00  
4/5/2019Torben Straight NissenPresidentSell12,596$20.00$251,920.00  
3/15/2019Christopher L CarpenterInsiderSell48,000$15.84$760,320.00  
7/20/2018Francis M CussDirectorBuy10,000$23.00$230,000.00  
(Data available from 1/1/2013 forward)
This page was last updated on 4/16/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.